Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gilead to buy Kite...

    Gilead to buy Kite Pharma for about 12 billion dollars

    Written by savita thakur thakur Published On 2017-08-29T11:55:18+05:30  |  Updated On 29 Aug 2017 11:55 AM IST
    Gilead to buy Kite Pharma for about 12 billion dollars

    Gilead Sciences Inc has agreed to buy immunotherapy developer Kite Pharma Inc in an all-cash deal valued at 11.9 dollars billion, the companies said.


    Gilead will pay 180 dollars per share, representing a 29.4 percent premium over Kite's Friday close.


    Gilead's growth has been fueled by its pricey but revolutionary hepatitis C drugs but with fewer eligible patients and rising competition, sales have begun to fall.


    Wall Street and Gilead shareholders have long been expecting the company to use its cash pile for a big-ticket acquisition to reinvigorate its sales growth.


    The deal, which has been approved by the boards of both companies, is expected to close in the fourth quarter of 2017.


    Kite is one of the leading players in an emerging field called CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body's own immune cells to recognize and attack malignant cells.


    If approved by the FDA, CAR-T therapies could cost up to 500,000 dollars and generate billions of dollars for their developers, analysts expect.


    Kite Pharma's experimental drug axi-cel is under expedited U.S. review for advanced non-Hodgkin lymphoma, with additional trials under way in leukemia patients.


    The Wall Street Journal first reported the deal on Monday.


    Kite's shares were halted in premarket trading on Monday, while Gilead's shares were up 2.7 percent.

    buyCAR-T therapieschimeric antigen receptorGilead SciencesGilead Sciences Inchepatitis C drugKite PharmaNon-Hodgkin LymphomaT cell therapytakeoverUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok